Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Accounts Payables: 2020-2025

Historic Accounts Payables for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $3.8 million.

  • Caribou Biosciences' Accounts Payables rose 40.68% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 40.68%. This contributed to the annual value of $2.5 million for FY2024, which is 20.64% down from last year.
  • As of Q3 2025, Caribou Biosciences' Accounts Payables stood at $3.8 million, which was up 17.30% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Accounts Payables ranged from a high of $5.9 million in Q1 2024 and a low of $426,000 during Q2 2022.
  • Moreover, its 3-year median value for Accounts Payables was $3.2 million (2024), whereas its average is $3.4 million.
  • In the last 5 years, Caribou Biosciences' Accounts Payables crashed by 89.43% in 2022 and then skyrocketed by 940.61% in 2023.
  • Quarterly analysis of 5 years shows Caribou Biosciences' Accounts Payables stood at $4.0 million in 2021, then plummeted by 71.28% to $1.1 million in 2022, then spiked by 172.25% to $3.1 million in 2023, then fell by 20.64% to $2.5 million in 2024, then surged by 40.68% to $3.8 million in 2025.
  • Its Accounts Payables was $3.8 million in Q3 2025, compared to $3.2 million in Q2 2025 and $3.9 million in Q1 2025.